Pfizer facing lower revenues as sales of covid vaccines fall

Drugmaker expects revenue for the year in the range of $59.5bn (€50.5bn) to $62.5bn (€53.1bn)

Pfizer CEO Albert Bourla. Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its covid products. Picture: Jeenah Moon/Bloomberg

Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects a steep drop in sales of its covid products and a revenue hit from the loss of exclusivity on some drugs.

Investors were keenly awaiting Pfizer's forecast to see if CEO Albert Bourla's cost-cutting measures, new product launches and steady demand for older drugs were helping offset a decline in COVID-related sales.